Hormone replacement therapy increases isometric muscle strength of adductor pollicis in post-menopausal women

1999 ◽  
Vol 96 (4) ◽  
pp. 357-364 ◽  
Author(s):  
D. A. SKELTON ◽  
S. K. PHILLIPS ◽  
S. A. BRUCE ◽  
C. H. NAYLOR ◽  
R. C. WOLEDGE
Keyword(s):  
Bone Mineral Density ◽  
Muscle Strength ◽  
Bone Mineral ◽  
Hormone Replacement ◽  
Treated Group ◽  
Control Group ◽  
Sectional Area ◽  
Mineral Density ◽  
Cross Sectional ◽  
Post Menopausal

A randomized open trial of hormone replacement therapy was used to assess changes in adductor pollicis muscle strength during 6–12 months of treatment with Prempak C 0.625® in comparison with an untreated control group. Muscle strength (maximal voluntary force; MVF), muscle cross-sectional area and bone mineral density were measured. Women entering the trial had oestrogen levels below 150 pmolċl-1, confirming their post-menopausal hormonal status. In the treated group, MVF increased by 12.4±1.0% (mean±S.E.M.) of initial MVF over the duration of treatment, while it declined slightly (2.9±0.9%) in the control group. This increase in strength could not be explained by an increase in muscle bulk, there being no significant increase in cross-sectional area during the study. Those subjects who were weakest at enrolment showed the greatest increases in muscle strength after treatment. Bone mineral density in total hip, Ward's triangle and total spine increased in the treated group, in agreement with previous studies. There was no correlation between the individual increases in bone mineral density and those in MVF.

scholarly journals The Association Between Hip Muscle Cross-Sectional Area, Muscle Strength, and Bone Mineral Density

2014 ◽  
Vol 95 (1) ◽  
pp. 64-72 ◽  
Author(s):  
Harbeer Ahedi ◽  
Dawn Aitken ◽  
David Scott ◽  
Leigh Blizzard ◽  
Flavia Cicuttini ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Muscle Strength ◽  
Bone Mineral ◽  
Cross Sectional Area ◽  
Sectional Area ◽  
Mineral Density ◽  
Cross Sectional ◽  
Hip Muscle ◽  
Muscle Cross Sectional Area

Relationship among running mileage, bone density, and serum testosterone in male runners

1992 ◽  
Vol 73 (3) ◽  
pp. 1165-1170 ◽  
Author(s):  
J. D. MacDougall ◽  
C. E. Webber ◽  
J. Martin ◽  
S. Ormerod ◽  
A. Chesley ◽  
...  
Keyword(s):  
Bone Density ◽  
Bone Mineral ◽  
Cross Sectional Area ◽  
Whole Body ◽  
Control Group ◽  
Dual Photon Absorptiometry ◽  
Sectional Area ◽  
Mineral Density ◽  
Cross Sectional ◽  
Density Measurements

Our purpose was to investigate the relationship between running volume and bone mineral mass in adult male runners. Whole body and regional bone mineral density were determined by dual-photon absorptiometry in 22 sedentary controls and 53 runners who were selected according to their running mileage to fall into a 5- to 10-, 15- to 20-, 25- to 30-, 40- to 55-, or 60- to 75-mile/wk group. All groups were of similar age (20–45 yr) and nutritional status, as determined by 7-day food records. Regional sites for bone density measurements included the trunk, spine, pelvis, thighs, and lower legs. In addition, serum total testosterone was determined in each subject and computed tomography scans were made of the lower legs in 34 subjects to assess bone cross-sectional area. No significant differences were detected for bone density measurements with the exception of the lower legs where it was significantly (P less than 0.05) greater for the 15- to 20-mile/wk group than for the control and 5- to 10-mile/wk groups. With mileage greater than 20 miles/wk, bone density of the lower legs showed no further increase and, in fact, tended to decrease, so that for the 60- to 75-mile/wk group it was similar to that of the controls. Cross-sectional area of the tibia and fibula when normalized to body weight tended to be greater as weekly mileage increased and was significantly greater in the 40- to 55-mile/wk runners than in the control group.(ABSTRACT TRUNCATED AT 250 WORDS)

BONE MINERAL DENSITY WOMEN AGED 45 AND OLDER WITH OVERWEIGHT AND OBESITY

2018 ◽  
pp. 109-113
Author(s):  
Ngoc Giang Luu ◽  
Anh Thu Le ◽  
Hai Thuy Nguyen
Keyword(s):  
Bone Mineral Density ◽  
Lumbar Spine ◽  
Bone Mineral ◽  
Overweight And Obesity ◽  
Control Group ◽  
Mineral Density ◽  
Femoral Bone Mineral Density ◽  
Cross Sectional ◽  
Osteoporosis Risk Factors ◽  
Key Words Bone

Objectives: (1) To assess the bone mineral density by dual energy X-ray absorptiometry in women aged 45 and older with overweight, obesity. (2) To approach the relationship between the bone mineral density and osteoporosis risk factors in women aged 45 and older with overweight, obesity. Materials and method: 207 women aged 45 and older receiving treatment at Medic - Binh Duong hospital were divided into 2 groups: 147 women with overweight, obesity and 60 women without overweight, obesity. Research was designed as a cross-sectional descriptive study and comparative control group. Results: The femoral bone mineral density in terms of women with overweight, obesity is (0.795 ± 0.121) and the control group is (0.731± 0.116). The bone mineral density of lumbar spine in women with overweight, obesity is (0.800 ± 0.138) and the control group is (0.757 ± 0.148). Conclusions: The bone mineral of femora in women with overweight, obesity was higher than that of the control group (p<0.05). Between two groups, there were no differences in the bone mineral of lumbar spine (p>0.05). There was a statistically significant relationship between the bone mineral density and age, menopause state, and duration of menopause in women aged 45 and older with overweight, obesity (p<0.01). Key words: Bone mineral density, women aged 45 and older, overweight, obesity

Relation between Circulating Vitamin k2 level and Osteoporosis in Post-Menopausal Women

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Dina M Abdel Aziz ◽  
Hala A Saleh ◽  
Neven M Taha ◽  
Mohga A Elbadawy
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Liver Function Tests ◽  
Thyroid Stimulating Hormone ◽  
Vitamin K2 ◽  
Mineral Density ◽  
Laboratory Assessment ◽  
Cross Sectional ◽  
Post Menopausal Osteoporosis ◽  
Post Menopausal

Abstract Objective We aimed to measure the serum level of vitamin k2 in postmenopausal osteoporotic patients to determine its role in the disease. Patients and Methods Our study was designed as a cross sectional study, with 15 postmenopausal osteoporotic patients (with reduced bone mineral density BMD), aged between 54-58 years old compared to 15 healthy controls (with normal BMD at all of lumbar spine, femoral neck and hip) matched in age with the patients. All participants were subjected to full medical history taking, physical examination and functional assessment of the activity of daily livings (ADL). Biochemical assays of thyroid stimulating hormone, parathyroid hormone, total calcium, phosphorus, alkaline phosphatase (ALP), 25-hydroxyvitamin D (25 (OH) D), erythrocyte sedimentation rate, Kidney and liver function tests and serum levels of vitamin k2 were performed. Results The patients showed highly significantly lower vitamin k2 levels (P &lt; 0.05) and non-significant correlations between vitamin k2 and the activity of daily living (ADL) nor the other laboratory assessment parameters (P &gt; 0.05) among the patient’s group. Conclusion Vitamin K deficiency is highly prevalent in the majority of our patients and should be considered an associating factor in the etiology of postmenopausal osteoporosis. Vitamin k2 deficiency could result in a decrease in the bone mineral density in postmenopausal women, so vitamin k2 levels should be checked in post-menopausal osteoporosis and any deficiency must be treated and corrected to improve the bone mineral density.

scholarly journals Effects of Olanzapine on Bone Mineral Density, Glucose, and Lipid Metabolism in Schizophrenia Patients

2019 ◽  
Vol 2019 ◽  
pp. 1-9 ◽  
Author(s):  
Mining Liang ◽  
Beibei Zhang ◽  
Lu Deng ◽  
Rong Xu ◽  
Haishan Wu ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Lipid Metabolism ◽  
Bone Mineral ◽  
Treated Group ◽  
Control Group ◽  
Mineral Density ◽  
Insulin Levels ◽  
Glucose And Lipid Metabolism ◽  
History Of ◽  
Drug Naïve

Aim. To explore whether olanzapine alters bone mineral density (BMD), glucose, and lipid metabolism in schizophrenia patients. Methods. This study enrolled 150 patients diagnosed with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), including 101 patients who had over 6-month history of olanzapine use (olanzapine-treated group) and 49 patients who had no history of antipsychotic use (first episode drug-naïve group). 71 subjects with age- and gender-matched healthy volunteers (healthy control group) were also enrolled. All study subjects were from the Chinese Han population recruited in the Second Xiangya Hospital from January 2015 to January 2016. Demographic and physical examination data were collected from all subjects. BMD measurements of the radius+ulna, lumbar spine (L1-4), and left hip were performed via a dual-energy X-ray absorptiometry test. Serum lipid, glucose, and insulin levels were analyzed. Psychopathology profiles in all enrolled schizophrenia patients were assessed by the positive and negative syndrome scale (PANSS). Results. There was no significant difference in age, gender, activity intensity, smoking, or drinking among the three groups. In the majority of evaluated bone areas, the BMD values in olanzapine-treated or drug-naïve patients were lower than those in the control group. However, BMD values in the drug-naïve group showed no difference or even decreased as compared with those in the olanzapine-treated group. Among the olanzapine-treated group, although not observed in every tested region, a positive correlation was found of BMI or HOMA-IR with BMD. Stepwise multiple linear regression analysis revealed independent predictive factors associated with BMD in groups/subgroups of schizophrenia patients or healthy controls, including gender, TG, BMI, body weight, HOMA-IR, and FBG. Conclusions. Schizophrenia, but not the long-term use of olanzapine, correlates with BMD loss in schizophrenia patients. Elevated BMI, TG, FBG, and insulin levels might protect these patients against bone degradation. Our work provides new information to improve the understanding, prevention, and treatment of osteoporosis in schizophrenia patients.

Sign in / Sign up

Export Citation Format

Share Document